Advertisement

Metabolomics

, 15:57 | Cite as

Disturbed energy and amino acid metabolism with their diagnostic potential in mitral valve disease revealed by untargeted plasma metabolic profiling

  • Limiao JiangEmail author
  • Jing Wang
  • Rui Li
  • Ze-min Fang
  • Xue-Hai Zhu
  • Xin Yi
  • Hongwen Lan
  • Xiang Wei
  • Ding-Sheng JiangEmail author
Original Article

Abstract

Introduction

Mitral valve disease (MVD), including mitral valve regurgitation (MR) and mitral valve stenosis (MS), is a chronic and progressive cardiac malady. However, the metabolic alterations in MVD is not well-understood till now. The current gold standard diagnostic test, transthoracic echocardiography, has limitations on high-throughput measurement and lacks molecular information for early diagnosis of the disease.

Objective

The present study aimed to investigate the biochemical alterations and to explore their diagnostic potential for MVD.

Methods

Plasma metabolic profile derangements and their diagnostic potential were non-invasively explored in 34 MR and 20 MS patients against their corresponding controls, using high-throughput NMR-based untargeted metabolomics.

Results

Eighteen differential metabolites were identified for MR and MS patients respectively, on the basis of multivariate and univariate data analysis, which were mainly involved in energy metabolism, amino acid metabolism, calcium metabolism and inflammation. These differential metabolites, notably the significantly down-regulated formate and lactate, showed high diagnostic potential for MVD by using Spearman’s rank-order correlation analysis and ROC analysis.

Conclusions

To the best of our knowledge, the present study is the first one that explores the metabolic derangements and their diagnostic values in MVD patients using metabolomics. The findings indicated that metabolic disturbance occurred in MVD patients, with plasma formate and lactate emerged as important candidate biomarkers for MVD.

Keywords

Mitral valve regurgitation Mitral valve stenosis Metabolomics NMR Formate Lactate 

Notes

Acknowledgements

The authors gratefully acknowledge the participation of all patients and healthy controls. The authors thank Professor An Pan (HUST) for his valuable comments and constructive suggestions. The authors gratefully acknowledge Dr Junfang Wu for the kind help on language editing during manuscript revision.

Author contributions

LJ, DSJ, ZMF, XHZ and XW designed the study. JW, RL, HWL and XY collected samples. LJ conduced the NMR experiment and analyzed the metabolomics data. LJ, JW, RL, HWL and XY analyzed the data. LJ, JW, and DSJ wrote the manuscript. LJ, JW, DSJ, ZMF, XHZ and XW revised the manuscript.

Funding

This work was supported by Grants from the National Natural Science Foundation of China (Nos. 81600188, 81670050), the Natural Science Foundation of Hubei Province (No. 2016CFB162), the Tongji Hospital Fund for Distinguished Young Scholars (No. 2016YQ02), Integrated Innovative Team for Major Human Diseases Program of Tongji Medical College, Huazhong University of Science and Technology, and the start-up grant from Huazhong University of Science and Technology (513-3004513113).

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in this study were in accordance with the ethical standards of the ethics committee of Tongji Hospital, Huazhong University of Science and Technology (HUST) and with the 1964 Helsinki declaration and its later amendments. Informed consent was obtained from all individual participants included in the study.

Supplementary material

11306_2019_1518_MOESM1_ESM.docx (2.3 mb)
Supplementary material 1 (DOCX 2365 kb)

References

  1. Abramowitz, Y., Jilaihawi, H., Chakravarty, T., Mack, M. J., & Makkar, R. R. (2015). Mitral annulus calcification. Journal of the American College of Cardiology, 66, 1934–1941.CrossRefGoogle Scholar
  2. Aubert, G., Martin, O. J., Horton, J. L., Lai, L., Vega, R. B., Leone, T. C., et al. (2016). The failing heart relies on ketone bodies as a fuel. Circulation, 133, 698–705.CrossRefGoogle Scholar
  3. Bakirel, U., & Gunes, S. (2009). Value of cardiac markers in dogs with chronic mitral valve disease. Acta Veterinaria-Beograd, 59, 223–229.CrossRefGoogle Scholar
  4. Baumgartner, H., Falk, V., Bax, J. J., De Bonis, M., Hamm, C., Holm, P. J., et al. (2017). 2017 ESC/EACTS guidelines for the management of valvular heart disease the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 38, 2739–2791.CrossRefGoogle Scholar
  5. Bell, J. D., Brown, J. C., Nicholson, J. K., & Sadler, P. J. (1987). Assignment of resonances for ‘acute-phase’ glycoproteins in high resolution proton NMR spectra of human blood plasma. FEBS Letters, 215, 311–315.CrossRefGoogle Scholar
  6. Cheng, M. L., Wang, C. H., Shiao, M. S., Liu, M. H., Huang, Y. Y., Huang, C. Y., et al. (2015). Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure diagnostic and prognostic value of metabolomics. Journal of the American College of Cardiology, 65, 1509–1520.CrossRefGoogle Scholar
  7. Christensen, K. E., Rohlicek, C. V., Andelfinger, G. U., Michaud, J., Bigras, J. L., Richter, A., et al. (2009). The MTHFD1 p.Arg653Gln variant alters enzyme function and increases risk for congenital heart defects. Human Mutation, 30, 212–220.CrossRefGoogle Scholar
  8. Conway, M. A., Bottomley, P. A., Ouwerkerk, R., Radda, G. K., & Rajagopalan, B. (1998). Mitral regurgitation: Impaired systolic function, eccentric hypertrophy, and increased severity are linked to lower phosphocreatine/ATP ratios in humans. Circulation, 97, 1716–1723.CrossRefGoogle Scholar
  9. Disatian, S., Lacerda, C., & Orton, E. C. (2010). Tryptophan hydroxylase 1 expression is increased in phenotype-altered canine and human degenerative myxomatous mitral valves. Journal of Heart Valve Disease, 19, 71–78.PubMedGoogle Scholar
  10. Duprez, D. A., Otvos, J., Sanchez, O. A., Mackey, R. H., Tracy, R., & Jacobs, D. R. (2016). Comparison of the predictive value of glyca and other biomarkers of inflammation for total death, incident cardiovascular events, noncardiovascular and noncancer inflammatory-related events, and total cancer events. Clinical Chemistry, 62, 1020–1031.CrossRefGoogle Scholar
  11. Elferink, S., Krooneman, J., Gottschal, J. C., Spoelstra, S. F., Faber, F., & Driehuis, F. (2001). Anaerobic conversion of lactic acid to acetic acid and 1,2-propanediol by Lactobacillus buchneri. Applied and Environmental Microbiology, 67, 125–132.CrossRefGoogle Scholar
  12. Elliott, B. A., & Wilkinson, J. H. (1961). Serum “α-hydroxybutyric dehydrogenase” in myocardial infarction and in liver disease. Lancet, 277, 698–699.CrossRefGoogle Scholar
  13. Eriksson, L., Trygg, J., & Wold, S. (2008). CV-ANOVA for significance testing of PLS and OPLS® models. Journal of Chemometrics, 22, 594–600.CrossRefGoogle Scholar
  14. Fan, Y., Li, Y., Chen, Y., Zhao, Y. J., Liu, L. W., Li, J., et al. (2016). Comprehensive metabolomic characterization of coronary artery diseases. Journal of the American College of Cardiology, 68, 1281–1293.CrossRefGoogle Scholar
  15. Gall, W. E., Beebe, K., Lawton, K. A., Adam, K. P., Mitchell, M. W., Nakhle, P. J., et al. (2010). α-Hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS ONE, 5, e10883.CrossRefGoogle Scholar
  16. Gowda, G. A. N., Gowda, Y. N., & Raftery, D. (2015). Expanding the limits of human blood metabolite quantitation using NMR spectroscopy. Analytical Chemistry, 87, 706–715.CrossRefGoogle Scholar
  17. Gregory, J. F., Cuskelly, G. J., Shane, B., Toth, J. P., Baumgartner, T. G., & Stacpoole, P. W. (2000). Primed, constant infusion with [2H3]serine allows in vivo kinetic measurement of serine turnover, homocysteine remethylation, and transsulfuration processes in human one-carbon metabolism. American Journal of Clinical Nutrition, 72, 1535–1541.CrossRefGoogle Scholar
  18. Harold, J. G., Jacobovitz, S., Oetgen, W. J., May, C. L., Bradfield, L., Cottrell, E., et al. (2014). 2014 AHA/ACC guideline for the management of patients with valvular heart disease. Journal of the American College of Cardiology, 63, E57–E185.CrossRefGoogle Scholar
  19. Heemskerk, M. M., van Harmelen, V. J. A., van Dijk, K. W., & van Klinken, J. B. (2016). Reanalysis of mGWAS results and in vitro validation show that lactate dehydrogenase interacts with branched-chain amino acid metabolism. European Journal of Human Genetics, 24, 142–145.CrossRefGoogle Scholar
  20. Hu, P., Liu, X. B., Liang, J., Zhu, Q. F., Pu, C. X., Tang, M. Y., et al. (2017). A hospital-based survey of patients with severe valvular heart disease in China. International Journal of Cardiology, 231, 244–247.CrossRefGoogle Scholar
  21. Iung, B., & Vahanian, A. (2011). Epidemiology of valvular heart disease in the adult. Nature Reviews Cardiology, 8, 162–172.CrossRefGoogle Scholar
  22. Jiang, L. M., Huang, J., Wang, Y. L., & Tang, H. R. (2012a). Eliminating the dication-induced intersample chemical-shift variations for NMR-based biofluid metabonomic analysis. Analyst, 137, 4209–4219.CrossRefGoogle Scholar
  23. Jiang, L. M., Huang, J., Wang, Y. L., & Tang, H. R. (2012b). Metabonomic analysis reveals the CCl4-induced systems alterations for multiple rat organs. Journal of Proteome Research, 11, 3848–3859.CrossRefGoogle Scholar
  24. Levine, R. A., Hagege, A. A., Judge, D. P., Padala, M., Dal-Bianco, J. P., Aikawa, E., et al. (2015). Mitral valve disease morphology and mechanisms. Nature Reviews Cardiology, 12, 689–710.CrossRefGoogle Scholar
  25. Li, Q. H., Freeman, L. M., Rush, J. E., Huggins, G. S., Kennedy, A. D., Labuda, J. A., et al. (2015). Veterinary medicine and multi-omics research for future nutrition targets: Metabolomics and transcriptomics of the common degenerative mitral valve disease in dogs. Omics: A Journal of Integrative Biology, 19, 461–470.CrossRefGoogle Scholar
  26. Liebich, H. M., & Forst, C. (1984). Hydroxycarboxylic and oxocarboxylic acids in urine: Products from branched-chain amino acid degradation and from ketogenesis. Journal of Chromatography, 309, 225–242.CrossRefGoogle Scholar
  27. Lin, X., Adams, S. H., & Odle, J. (1996). Acetate represents a major product of hepatonate and octanoate beta-oxidation in hepatocytes isolated from neonatal piglets. Biochemical Journal, 318, 235–240.CrossRefGoogle Scholar
  28. Mourino-Alvarez, L., Baldan-Martin, M., Gonzalez-Calero, L., Martinez-Laborde, C., Sastre-Oliva, T., Moreno-Luna, R., et al. (2016). Patients with calcific aortic stenosis exhibit systemic molecular evidence of ischemia, enhanced coagulation, oxidative stress and impaired cholesterol transport. International Journal of Cardiology, 225, 99–106.CrossRefGoogle Scholar
  29. Mueller-Hennessen, M., Dungen, H. D., Lutz, M., Trippel, T. D., Kreuter, M., Sigl, J., et al. (2017). A novel lipid biomarker panel for the detection of heart failure with reduced ejection fraction. Clinical Chemistry, 63, 267–277.CrossRefGoogle Scholar
  30. Nakae, I., Mitsunami, K., Matsuo, S., Inubushi, T., Morikawa, S., Tsutamoto, T., et al. (2005). Myocardial creatine concentration in various nonischemic heart diseases assessed by H-1 magnetic resonance spectroscopy. Circulation Journal, 69, 711–716.CrossRefGoogle Scholar
  31. Nicholson, J. K., Connelly, J., Lindon, J. C., & Holmes, E. (2002). Metabonomics: A platform for studying drug toxicity and gene function. Nature Reviews Drug Discovery, 1, 153–161.CrossRefGoogle Scholar
  32. Nicholson, J. K., Foxall, P. J. D., Spraul, M., Farrant, R. D., & Lindon, J. C. (1995). 750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. Analytical Chemistry, 67, 793–811.CrossRefGoogle Scholar
  33. Nkomo, V. T., Gardin, J. M., Skelton, T. N., Gottdiener, J. S., Scott, C. G., & Enriquez-Sarano, M. (2006). Burden of valvular heart diseases: A population-based study. Lancet, 368, 1005–1011.CrossRefGoogle Scholar
  34. Olkowicz, M., Debski, J., Jablonska, P., Dadlez, M., & Smolenski, R. T. (2017). Application of a new procedure for liquid chromatography/mass spectrometry profiling of plasma amino acid-related metabolites and untargeted shotgun proteomics to identify mechanisms and biomarkers of calcific aortic stenosis. Journal of Chromatography A, 1517, 66–78.CrossRefGoogle Scholar
  35. Orton, E. C., Lacerda, C. M. R., & MacLea, H. B. (2012). Signaling pathways in mitral valve degeneration. Journal of Veterinary Cardiology, 14, 7–17.CrossRefGoogle Scholar
  36. Paynter, N. P., Balasubramanian, R., Giulianini, F., Wang, D. D., Tinker, L. F., Gopal, S., et al. (2018). Metabolic predictors of incident coronary heart disease in women. Circulation, 137, 841–853.CrossRefGoogle Scholar
  37. Rosalki, S. B., & Wilkinson, J. H. (1964). Serum α-hydroxybutyrate dehydrogenase in diagnosis. JAMA, 189, 61–63.CrossRefGoogle Scholar
  38. Ruiz-Canela, M., Toledo, E., Clish, C. B., Hruby, A., Liang, L. M., Salas-Salvado, J., et al. (2016). Plasma branched-chain amino acids and incident cardiovascular disease in the PREDIMED trial. Clinical Chemistry, 62, 582–592.CrossRefGoogle Scholar
  39. Schonfeld, P., & Wojtczak, L. (2016). Short- and medium-chain fatty acids in energy metabolism: The cellular perspective. Journal of Lipid Research, 57, 943–954.CrossRefGoogle Scholar
  40. Sylven, C., Jansson, E., Szamosi, A., & Book, K. (1989). Key enzymes of myocardial energy metabolism in papillary muscle of patients with mitral valve disease—Relation to left-ventricular function. Scandinavian Journal of Thoracic and Cardiovascular Surgery, 23, 63–67.CrossRefGoogle Scholar
  41. van Beynum, I. M., Kapusta, L., Bakker, M. K., den Heijer, M., Blom, H. J., & de Walle, H. E. K. (2010). Protective effect of periconceptional folic acid supplements on the risk of congenital heart defects: A registry-based case-control study in the northern Netherlands. European Heart Journal, 31, 464–471.CrossRefGoogle Scholar
  42. Wang, W. S., Maimaiti, A., Zhao, Y., Zhang, L. F., Tao, H. Y., Nian, H., et al. (2016). Analysis of serum metabolites to diagnose bicuspid aortic valve. Scientific Reports, 6, 37023.CrossRefGoogle Scholar
  43. Xia, J. G., Sinelnikov, I. V., Han, B., & Wishart, D. S. (2015). MetaboAnalyst 3.0—Making metabolomics more meaningful. Nucleic Acids Research, 43, W251–W257.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Epidemiology and Biostatistics, MOE Key Laboratory of Environment and Health, School of Public Health, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  2. 2.Division of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  3. 3.Key Laboratory of Organ TransplantationMinistry of EducationWuhanChina
  4. 4.NHC Key Laboratory of Organ TransplantationWuhanChina
  5. 5.Key Laboratory of Organ TransplantationChinese Academy of Medical SciencesWuhanChina
  6. 6.Department of CardiologyRenmin Hospital of Wuhan UniversityWuhanChina
  7. 7.Cardiovascular Research InstituteWuhan UniversityWuhanChina
  8. 8.Hubei Key Laboratory of CardiologyWuhanChina

Personalised recommendations